{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"condition":["diabetes, non-alcoholic lipid liver disease / non-alcoholicity fat hepatitis, inflammatory bowel disease (ulcerative colitis, Crohn’s disease), irritable bowel disease, neuroimmune disease, lung cancer, esophageal cancer, gastric cancer, colorectal cancer"],"disease":["Diabetes, Non-alcoholic Lipid Liver Disease / Non-alcoholicity Fat Hepatitis, Inflammatory Bowel Disease (ulcerative Colitis, Crohn’s Disease), Irritable Bowel Disease, Neuroimmune Disease, Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2634775"],"location":["Japan"],"study_start_month":["2"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Enterobacterial analysis for the precise medical care (precision medicine) for diabetes, non-alcoholic lipid liver disease / non-alcoholicity fat hepatitis, inflammatory bowel disease, and irritable bowel syndrome.","description":"Primary outcome(s): Tendency of the enterobacterial flora of each disease compared to healthy control.","dates":{"creation":"2016-02-15"},"accession":"2634775","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000019486"]}}